Lv61
2500 积分 2023-08-04 加入
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
4小时前
待确认
Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
12天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
20天前
已完结
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
24天前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
24天前
已完结
Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer
26天前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
26天前
已完结
Bemarituzumab enters the FIGHT
26天前
已完结
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer
1个月前
已完结
皖公网安备34019202002308
